[A novel approach to HLA-mismatched transplantation].

Objective: To investigate the new methods of human leukocyte antigen (HLA) mismatched transplantation in patients with hematologic malignancies.

Methods: In this pilot study, 58 patients, 33 with high-risk or advanced leukemia, were transplanted with cells from an HLA-haploidentical family donor with at least 1 of 6 loci mismatched. After conditioning, patients received non ex vivo, T cell-depleted grafts of G-CSF-primed bone marrow plus G-CSF-mobilized peripheral blood stem cells, as well as graft-versus-host-disease (GVHD) prophylaxis.

[Allogeneic hematopoietic stem cell transplantation for acute lymphocytic leukemia].

Objective: To retrospectively analyze the results of a consecutive series of 100 ALL patients received allogeneic hematopoietic stem cell transplantation (allo-HSCT) in our center.

Methods: Of the 100 ALL patients, 69 were male and 31 female, with a median age of 29.5 (4 - 47) years.

[Detection of cytomegalovirus infection by polymerase chain reaction in hematopoietic stem cell transplantation recipients].

Objective: To evaluate the detection of cytomegalovirus (CMV) by polymerase chain reaction (PCR) for predicting the development of CMV disease.

Methods: One hundred and thirty one allo-HSCT patients performed in the past 2 years were analyzed retrospectively. PCR-CMV was used to monitor CMV viremia and vireuria once a week after transplantation.

[Cytomegalovirus diseases after allogeneic hematopoietic stem cell transplantation (Allo-HSCT) and related risk factors].

Objective: To analyze the incidence of cytomegalovirus (CMV) diseases after allogeneic hematopoietic stem cell transplantation (allo-HSCT) and related risk factors.

Methods: The clinical data of 131 patients undergoing allo-HSCT August 1999 to July 2001 were analyzed retrospectively.

Results: Twenty-eight of the 131 patients developed CMV interstitial pneumonia (IP) with an incidence rate of 21.

[Treatment of severe steroid-refractory graft-versus-host disease with IL-2R alpha chain (CD25) monoclonal antibody].

Objective: To investigate the effects of IL-2R alpha chain (CD(25)) monoclonal antibody on severe steroid-refractory graft-versus-host disease (GVHD).

Methods: Seventeen patients (18 times) with severe steroid-refractory GVHD were treated with intravenous drip of humanized CD(25) monoclonal antibody on day 1, 3 or 4, 8, 15 and 22. The cumulative scoring of GVHD and status of infection were observed, and laboratory tests, including blood counting and blood biochemical test were made before and 1, 4, 8, 15, 22, 29, 36, 43 and 50 days after the treatment.

[Unrelated cord blood transplantation for the treatment of hematological malignancies].

Objectives: To investigate the engraftment, survival and graft-versus host disease (GVHD) after transplantation of unrelated cord blood for the treatment of childhood and adult hematological malignancies.

Methods: Seventeen patients (13 children and 4 adults) with hematological malignancies were enrolled in this study. Twelve patients were transplanted with one unit and 5 with 2 units of cord blood.

[Exploration of acute graft versus host disease and its risk factors after allo-hematopoietic stem cell transplantation].

Objective: To explore the incidence, prognosis and risk factors of the acute graft versus host disease (aGVHD) after allo-hematopoietic stem cell transplantation (allo-HSCT).

Methods: The clinical data of 118 cases undergone 120 times of allo-HSCT were analyzed.

Result: aGVHD was observed in 63 cases (52.